Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Ukrainian Anti-Cancer Institute is a Vienna-based organization founded by Dr. Wassil Nowicky to develop and promote Ukrain, a semi-synthetic alkaloid derivative of the plant Chelidonium majus. The institute claimed that Ukrain possessed selective cytotoxic effects against cancer cells by inducing apoptosis and inhibiting mitosis without damaging healthy tissue. Despite numerous small-scale clinical trials and publications, the drug never received approval from major regulatory bodies such as the EMA or FDA due to significant concerns regarding trial methodology and safety data. The institute's operations effectively ceased following a 2012 raid by Austrian authorities and subsequent legal proceedings involving the unauthorized sale of medicinal products. Today, the organization is primarily recognized for its controversial history and the lack of scientific consensus regarding its primary therapeutic candidate.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ukrainian Anti-Cancer Institute.